These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 29961686)

  • 21. Long-term outcomes in patients with polyarticular juvenile idiopathic arthritis receiving adalimumab with or without methotrexate.
    Lovell DJ; Brunner HI; Reiff AO; Jung L; Jarosova K; Němcová D; Mouy R; Sandborg C; Bohnsack JF; Elewaut D; Gabriel C; Higgins G; Kone-Paut I; Jones OY; Vargová V; Chalom E; Wouters C; Lagunes I; Song Y; Martini A; Ruperto N
    RMD Open; 2020 Jul; 6(2):. PubMed ID: 32665432
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Subcutaneous golimumab for children with active polyarticular-course juvenile idiopathic arthritis: results of a multicentre, double-blind, randomised-withdrawal trial.
    Brunner HI; Ruperto N; Tzaribachev N; Horneff G; Chasnyk VG; Panaviene V; Abud-Mendoza C; Reiff A; Alexeeva E; Rubio-Pérez N; Keltsev V; Kingsbury DJ; Del Rocio Maldonado Velázquez M; Nikishina I; Silverman ED; Joos R; Smolewska E; Bandeira M; Minden K; van Royen-Kerkhof A; Emminger W; Foeldvari I; Lauwerys BR; Sztajnbok F; Gilmer KE; Xu Z; Leu JH; Kim L; Lamberth SL; Loza MJ; Lovell DJ; Martini A;
    Ann Rheum Dis; 2018 Jan; 77(1):21-29. PubMed ID: 28507219
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Intravenous dosing of tocilizumab in patients younger than two years of age with systemic juvenile idiopathic arthritis: results from an open-label phase 1 clinical trial.
    Mallalieu NL; Wimalasundera S; Hsu JC; Douglass W; Wells C; Penades IC; Cuttica R; Huppertz HI; Joos R; Kimura Y; Milojevic D; Rosenkranz M; Schikler K; Constantin T; Wouters C
    Pediatr Rheumatol Online J; 2019 Aug; 17(1):57. PubMed ID: 31438986
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tocilizumab treatment in juvenile idiopathic arthritis patients: A single center experience.
    Demir S; Sönmez HE; Arslanoğlu-Aydın E; Özen S; Bilginer Y
    Turk J Pediatr; 2019; 61(2):180-185. PubMed ID: 31951328
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Serious adverse events in children with juvenile idiopathic arthritis and other rheumatic diseases on tocilizumab - a real-world experience.
    Aeschlimann FA; Dumaine C; Wörner A; Mouy R; Wouters C; Melki I; Uettwiller F; Job-Deslandre C; Quartier P; Bader-Meunier B
    Semin Arthritis Rheum; 2020 Aug; 50(4):744-748. PubMed ID: 32526594
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparisons of the outcomes between early and late tocilizumab treatment in systemic juvenile idiopathic arthritis.
    Pacharapakornpong T; Vallibhakara SA; Lerkvaleekul B; Vilaiyuk S
    Rheumatol Int; 2017 Feb; 37(2):251-255. PubMed ID: 27798725
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and safety of tocilizumab in a real-life observational cohort of patients with polyarticular juvenile idiopathic arthritis.
    Grönlund MM; Remes-Pakarinen T; Kröger L; Markula-Patjas K; Backström M; Putto-Laurila A; Aalto K; Vähäsalo P
    Rheumatology (Oxford); 2020 Apr; 59(4):732-741. PubMed ID: 31359057
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety and efficacy of tocilizumab, an anti-IL-6-receptor monoclonal antibody, in patients with polyarticular-course juvenile idiopathic arthritis.
    Imagawa T; Yokota S; Mori M; Miyamae T; Takei S; Imanaka H; Nerome Y; Iwata N; Murata T; Miyoshi M; Nishimoto N; Kishimoto T
    Mod Rheumatol; 2012 Feb; 22(1):109-15. PubMed ID: 21667343
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Discrepancy between clinical and radiological responses to tocilizumab treatment in patients with systemic-onset juvenile idiopathic arthritis.
    Aoki C; Inaba Y; Choe H; Kaneko U; Hara R; Miyamae T; Imagawa T; Mori M; Oba MS; Yokota S; Saito T
    J Rheumatol; 2014 Jun; 41(6):1171-7. PubMed ID: 24786929
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Growth in children and adolescents with juvenile idiopathic arthritis over 2 years of treatment with etanercept: results from the British Society for Paediatric and Adolescent Rheumatology Etanercept Cohort Study.
    Kearsley-Fleet L; Hyrich KL; Davies R; Lunt M; Southwood TR;
    Rheumatology (Oxford); 2015 Jul; 54(7):1279-85. PubMed ID: 25638806
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and safety of etanercept in patients with the enthesitis-related arthritis category of juvenile idiopathic arthritis: results from a phase III randomized, double-blind study.
    Horneff G; Foeldvari I; Minden K; Trauzeddel R; Kümmerle-Deschner JB; Tenbrock K; Ganser G; Huppertz HI
    Arthritis Rheumatol; 2015 May; 67(8):2240-9. PubMed ID: 25891010
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinically inactive disease in a cohort of children with new-onset polyarticular juvenile idiopathic arthritis treated with early aggressive therapy: time to achievement, total duration, and predictors.
    Wallace CA; Giannini EH; Spalding SJ; Hashkes PJ; O'Neil KM; Zeft AS; Szer IS; Ringold S; Brunner HI; Schanberg LE; Sundel RP; Milojevic DS; Punaro MG; Chira P; Gottlieb BS; Higgins GC; Ilowite NT; Kimura Y; Johnson A; Huang B; Lovell DJ;
    J Rheumatol; 2014 Jun; 41(6):1163-70. PubMed ID: 24786928
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of biologic treatments on growth in children with juvenile idiopathic arthritis.
    Uettwiller F; Perlbarg J; Pinto G; Bader-Meunier B; Mouy R; Compeyrot-Lacassagne S; Melki I; Wouters C; Prieur AM; Landais P; Polak M; Quartier P
    J Rheumatol; 2014 Jan; 41(1):128-35. PubMed ID: 24293576
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety, effectiveness, and pharmacokinetics of adalimumab in children with polyarticular juvenile idiopathic arthritis aged 2 to 4 years.
    Kingsbury DJ; Bader-Meunier B; Patel G; Arora V; Kalabic J; Kupper H
    Clin Rheumatol; 2014; 33(10):1433-41. PubMed ID: 24487484
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of anti-TNF treatment on growth in severe juvenile idiopathic arthritis.
    Tynjälä P; Lahdenne P; Vähäsalo P; Kautiainen H; Honkanen V
    Ann Rheum Dis; 2006 Aug; 65(8):1044-9. PubMed ID: 16449314
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety of tocilizumab in the treatment of juvenile idiopathic arthritis.
    Machado SH; Xavier RM
    Expert Opin Drug Saf; 2017 Apr; 16(4):493-500. PubMed ID: 28277841
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tocilizumab: a review of its use in the treatment of juvenile idiopathic arthritis.
    Frampton JE
    Paediatr Drugs; 2013 Dec; 15(6):515-31. PubMed ID: 24155139
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Successful treatment with tocilizumab every 4 weeks of a low disease activity group who achieve a drug-free remission in patients with systemic-onset juvenile idiopathic arthritis.
    Kostik MM; Dubko MF; Masalova VV; Snegireva LS; Kornishina TL; Chikova IA; Isupova EA; Kuchinskaya EM; Glebova NI; Buchinskaya NV; Kalashnikova OV; Chasnyk VG
    Pediatr Rheumatol Online J; 2015; 13():4. PubMed ID: 25685108
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tocilizumab for juvenile idiopathic arthritis: a single-center case series.
    Yazılıtaş F; Özdel S; Şimşek D; Aydoğ Ö; Çakıcı EK; Can GG; Güngör T; Bülbül M
    Sao Paulo Med J; 2019; 137(6):517-522. PubMed ID: 32159638
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Adalimumab with or without methotrexate in juvenile rheumatoid arthritis.
    Lovell DJ; Ruperto N; Goodman S; Reiff A; Jung L; Jarosova K; Nemcova D; Mouy R; Sandborg C; Bohnsack J; Elewaut D; Foeldvari I; Gerloni V; Rovensky J; Minden K; Vehe RK; Weiner LW; Horneff G; Huppertz HI; Olson NY; Medich JR; Carcereri-De-Prati R; McIlraith MJ; Giannini EH; Martini A; ;
    N Engl J Med; 2008 Aug; 359(8):810-20. PubMed ID: 18716298
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.